Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEDILANID-D vs ADALAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Heart failure,Atrial fibrillation,Atrial flutter
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
Terminal elimination half-life is 36-48 hours in patients with normal renal function; prolonged to >100 hours in severe renal impairment, requiring dose adjustment.
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Hepatic (minor); primarily renally excreted unchanged.
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 30-40%, with enterohepatic circulation present.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
25-30% bound to plasma albumin.
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
6-10 L/kg; large Vd indicates extensive tissue distribution and high cardiac tissue affinity.
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Oral: 70-80%; IV: 100%.
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
GFR <50 m L/min: reduce dose by 50% or extend dosing interval to every 36-48 hours. GFR <10 m L/min: avoid use or reduce dose by 75%.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: avoid use or reduce dose by 75%.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
Digitalizing dose: 0.01-0.02 mg/kg IV or IM, given in divided doses over 24 hours. Maintenance: 10-20% of digitalizing dose daily. Not recommended for neonates due to prolonged half-life.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
Reduce dose by 25-50% due to decreased renal function and increased sensitivity. Monitor serum levels and renal function closely.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
Can cause potentially fatal arrhythmias; use only when clearly indicated and monitor serum levels.
None
Narrow therapeutic index; toxicity risk increased with hypokalemia, hypomagnesemia, hypercalcemia, renal impairment; monitor ECG and drug levels.
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Ventricular fibrillation, digitalis toxicity, hypersensitivity, AV block (unless pacemaker present), Wolff-Parkinson-White syndrome.
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
Avoid licorice, which can cause hypokalemia. Maintain consistent intake of potassium-rich foods (bananas, oranges) to avoid fluctuations. No known significant food interactions beyond electrolyte effects.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal risk. Second/third trimester: Risk of fetal bradycardia, cardiac glycoside toxicity; avoids if possible.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
Deslanoside is excreted in breast milk; estimated infant dose 0.1-0.5% of maternal weight-adjusted dose; M/P ratio not well defined. Monitor infant for bradycardia, feeding difficulties; benefit likely outweighs risk.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
Increased renal clearance in pregnancy may require higher doses; monitor serum drug levels and adjust accordingly. Reduced dosing in third trimester may be needed due to volume expansion.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
Cedilanid-D (deslanoside) is a rapidly acting parenteral digitalis glycoside. Use with extreme caution in renal impairment due to reduced clearance. Monitor serum potassium and magnesium; hypokalemia and hypomagnesemia potentiate toxicity. Administer slow IV push over 5 minutes to avoid arrhythmias. Therapeutic drug monitoring less common due to short half-life of 33 hours. Contraindicated in ventricular tachycardia and AV block (unless due to atrial fibrillation).
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
Take exactly as prescribed; do not double doses.,Report symptoms of toxicity: nausea, vomiting, visual disturbances (yellow-green halos), irregular heartbeat.,Avoid over-the-counter medications without consulting doctor.,Maintain consistent potassium intake; avoid high-potassium foods or supplements unless advised.,Monitor daily weight and report rapid weight gain or edema.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CEDILANID-D vs ADALAT, answered by our medical review team.
CEDILANID-D is a Cardiac Glycoside that works by Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.. ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEDILANID-D and ADALAT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEDILANID-D is: 0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.. The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CEDILANID-D and ADALAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CEDILANID-D is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal risk. Second/third trimester: Risk of fetal bradycardia, cardiac glycoside toxicity; avo. ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.